1+ hour, 29+ min ago  (464+ words) -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- --March 20, 2026PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- Highlights from these 52-week data include: Primary…...

3+ hour, 33+ min ago  (1635+ words) Los Angeles, CA, March 01, 2026 (GLOBE NEWSWIRE) -- "CitrusBurn" is a newly released, plant-based metabolism support supplement specifically designed to address "thermogenic resistance." Released in early 2026, it is primarily marketed toward adults over 35 who are experiencing a natural metabolic slowdown. Know More…...

5+ hour, 59+ min ago  (856+ words) Could taking time out of the workforce to become a caregiver destroy someone's chances at a comfortable retirement?" For Susan Freeman, 72, the answer is yes. Although Freeman doesn't regret her decision to care for her mom, it destroyed her hope…...

9+ hour, 31+ min ago  (429+ words) Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced on February 27 that the US Food and Drug Administration approved three new indications for once-weekly…...

15+ hour, 32+ min ago  (631+ words) Pliant has pivoted from fibrosis to position itself as an integrin small-molecule platform company, advancing internal oncology programs and a targeted siRNA delivery platform while evaluating potential in'licensing or acquisition opportunities. Early Phase I data for oral PLN-101095 (v8/v1 inhibitor) showed…...

16+ hour, 55+ min ago  (357+ words) Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by…...

17+ hour, 14+ min ago  (213+ words) SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily" Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing…...

22+ hour, 35+ min ago  (457+ words) " Diamondback Sees Resilient Demand Despite Cautious Guidance According to Bohen, the field started with roughly ten drugs in the space, and it was "fairly predictable" that many would be flawed. He said the attrition contributed to skepticism about the class,…...

23+ hour, 34+ min ago  (476+ words) Ch'tillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN" Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group…...

1+ day, 27+ min ago  (538+ words) Strategic pivot and runway: Over the past 1218 months Kymera has refocused from oncology to immunology/inflammation, advancing six clinical IMiD degrader programs and reporting $1.6 billion in cash to fund operations into 2029. KT-621 (STAT6) progress: Phase Ib atopic dermatitis data showed strong…...